NCT00651443View on ClinicalTrials.gov

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2010

Conditions

Lymphoma, Non-Hodgkin's

Interventions

DRUG

Galiximab

Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.

Trial Locations (1)

14263

Research Site, Buffalo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY